T
Tobias Heintges
Publications - 40
Citations - 2886
Tobias Heintges is an academic researcher. The author has contributed to research in topics: FOLFIRI & Cetuximab. The author has an hindex of 16, co-authored 40 publications receiving 2401 citations.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Sebastian Stintzing,Sebastian Stintzing,Dominik Paul Modest,Dominik Paul Modest,Lisa Rossius,Markus M. Lerch,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,Clemens Giessen-Jung,Markus Moehler,Andreas Jagenburg,Thomas Kirchner,Thomas Kirchner,Andreas Jung,Andreas Jung,Volker Heinemann,Volker Heinemann +27 more
TL;DR: The FIRE-3 trial as discussed by the authors compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRi plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Sebastian Stintzing,Pratyaksha Wirapati,H. J. Lenz,Daniel Neureiter,L. Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Florian Kaiser,S-E. Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Markus Moehler,Werner Scheithauer,Swantje Held,Dominik Paul Modest,Andreas Jung,T. Kirchner,Dan Aderka,Sabine Tejpar,Volker Heinemann +22 more
TL;DR: CMS classification provides deeper insights into the biology to CRC, but at present time has no direct impact on clinical decision-making.
Journal ArticleDOI
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Sebastian Stintzing,Lisa Miller-Phillips,Dominik Paul Modest,L. Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,S.-E. Al-Batran,Tobias Heintges,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,M. Moehler,A. Jagenburg,Thomas Kirchner,Andreas Jung,Volker Heinemann +19 more
TL;DR: In BRAF- and RAS-mutant patients, cetuximab- and bevacizumab-based treatment had comparable survival times and ETS represents an early parameter associated with the benefit from anti-EGFR, while this was not the case with vascular endothelial growth factor A blockade.
Journal ArticleDOI
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Dominik Paul Modest,Sebastian Stintzing,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Svantje Held,Markus Möhler,Andreas Jung,Thomas Kirchner,Volker Heinemann +18 more
TL;DR: In patients with RAS wild-type tumors, first-line application of anti-epidermal growth factor receptor-directed therapy may represent a favorable condition for promoting effective subsequent therapy including antiangiogenic agents.